SVRA
Companies
NASDAQ
Savara Inc.
Health Care
$2.07
-$1.00 (-32.57%)
Price Chart
Overview
About SVRA
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Market Cap
$547.2M
Volume
2.0M
Avg. Volume
1.6M
P/E Ratio
-7.1395345
Dividend Yield
0.00%
Employees
39.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.89
Moderate Correlation
Volatility
High (0.59)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, SVRA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$547.2M
Volume2.0M
P/E Ratio-7.14
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025